Sign In
Buy ANIP
$79.24
-1.19 (-1.48%)
At Close: Jul 31, 2026
Why ANI (ANIP) Could Beat Earnings Estimates Again
01:11pm, Wednesday, 15'th Oct 2025
ANI (ANIP) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
09:50am, Wednesday, 15'th Oct 2025
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
01:46pm, Friday, 10'th Oct 2025
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year?
10:40am, Friday, 10'th Oct 2025
Here is how ANI Pharmaceuticals (ANIP) and Celldex Therapeutics (CLDX) have performed compared to their sector so far this year.
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Wednesday, 24'th Sep 2025
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
5 Biotech Stocks Worth Adding to Your Portfolio Now
10:25am, Tuesday, 23'rd Sep 2025
The volatile biotech industry has done reasonably well so far in 2025 amid the ongoing tariff saga. Most pharma/biotech bigwigs are now investing heavily in manufacturing plants/operations in the Unit
ANI Pharmaceuticals, Inc. (ANIP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
04:41pm, Tuesday, 09'th Sep 2025
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 1:50 PM EDT Company Participants Nikhil Lalwani - President, CEO & Director Conferenc
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
06:11pm, Monday, 08'th Sep 2025
ANI (ANIP) could produce exceptional returns because of its solid growth attributes.
ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue?
05:35pm, Monday, 08'th Sep 2025
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI Pharmaceuticals (ANIP) is a Great Momentum Stock: Should You Buy?
01:00pm, Thursday, 28'th Aug 2025
Does ANI Pharmaceuticals (ANIP) have what it takes to be a top stock pick for momentum investors? Let's find out.
ANI Pharmaceuticals to Present at Upcoming Investor Conferences
04:30pm, Monday, 25'th Aug 2025
PRINCETON, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer,
Is ANI (ANIP) a Solid Growth Stock? 3 Reasons to Think "Yes"
01:46pm, Friday, 22'nd Aug 2025
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI Pharmaceuticals, Inc. (ANIP) Hits Fresh High: Is There Still Room to Run?
10:15am, Friday, 22'nd Aug 2025
ANI (ANIP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
ANI (ANIP) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
10:31am, Monday, 11'th Aug 2025
While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wal
ANI Pharmaceuticals, Inc. (ANIP) Q2 2025 Earnings Call Transcript
03:56pm, Friday, 08'th Aug 2025
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP ) Q2 2025 Earnings Conference Call August 8, 2025 8:30 AM ET Company Participants Christopher K. Mutz - Senior VP & Head of Rare Disease Nikhil Lalwani - Preside
